If you've had a kidney stone, you know how much it hurts. But even though it's hard to forget the pain, over time it can be easy to forget the diet guidelines and daily medications that help prevent new stones. The truth is, patients who form just one kidney stone have a 50% higher risk of forming another stone in the next 5 to 10 years. If you've already had two or more stones, your risks of forming additional stones can be even higher.1

That's why continued compliance is your best protection against another kidney stone attack. But for many patients, it can be a real challenge to keep up with multitablet, multidose medication therapies.2,3

New Urocit®-K 15 mEq (1620 mg) potassium citrate tablets make compliance simpler

Urocit-K 15 mEq provides more active ingredient per tablet than other Urocit-K formulations, such as 10 mEq (1080 mg) potassium citrate and Urocit-K 5 mEq (540 mg) potassium citrate. This means you will need fewer pills per dose and may also need fewer doses over the course of the day. (Your doctor will tailor the exact dosing schedule to your individual medical requirements.)

How Urocit-K works

The key ingredient in Urocit-K is potassium citrate, which works by restoring naturally occurring chemicals in the urine that stop crystals from forming and also inhibits the formation of the 2 most common types of kidney stones, calcium oxalate and uric acid stones. In numerous studies, patients treated with Urocit-K have demonstrated significantly lower rates of kidney stone formation. In many patients, new stones do not form at all.4,5,6

A gentle, extended-release formula

A special wax-matrix delivery system in Urocit-K 15 mEq allows for extended-release of potassium citrate. This helps to maintain the targeted levels of urinary citrate and urinary pH that are important for continuous protection against crystal growth and stone formation. It also helps to ensure that your therapy is easy to tolerate because it is gentler on your digestive system.

Urocit®-K is a prescription form of potassium citrate. It helps restore the chemicals in urine that stop crystals from forming, and reduces the formation of the two most common types of kidney stones: calcium oxalate and uric acid stones.

Important Safety Information

Urocit®-K is not for everyone. It has not been tested on children, pregnant women, or women who are breastfeeding, and it is unknown whether Urocit®-K can affect reproductive capacity, unborn children, or breast milk content. You should not take Urocit®-K if you are pregnant, may become pregnant, or are currently breastfeeding, unless your doctor has discussed the risks with you and determined that it is necessary.

Certain drugs can interact with Urocit®-K and lead to increased gastrointestinal (GI) irritation. Drug interactions can also lead to hyperkalemia, an excess of potassium in your blood that could lead to cardiac arrest or death. These serious and possibly fatal conditions can develop rapidly with no noticeable symptoms. Always talk to your doctor about any medications you are taking before starting a prescription of Urocit®-K.

If you have hyperkalemia, or any condition that puts you at risk for the condition or prevents your body from processing potassium normally, do not take Urocit®-K because it could lead to cardiac arrest. Conditions that may put you at risk include kidney failure, uncontrolled diabetes, severe dehydration, strenuous physical exercise if you're unconditioned, extensive tissue breakdown, or adrenal insufficiency (when your adrenal glands do not produce the correct amount of chemicals needed to regulate the function of your organs).

Do not take Urocit®-K if you have an active urinary tract infection, peptic ulcer disease, or conditions that slow or prevent the tablet from passing through your GI tract, such as compression of the esophagus, delayed gastric emptying, or narrowing or blockage of your intestines.

Take Urocit®-K only as directed. Do not crush, chew, or suck on the tablets, and check with your doctor if you experience any trouble swallowing tablets or if they seem to get stuck in your throat.

To ensure your safety during your prescription, your doctor may perform regular blood tests and EKGs (which analyze the electrical activity in your heart).

Some patients taking Urocit®-K may develop minor GI side effects such as abdominal discomfort, vomiting, diarrhea, loose bowel movements or nausea. To reduce these effects, take each dose of Urocit®-K with meals or snacks, or talk to your doctor about reducing the amount of your dosage.

If you experience severe vomiting, abdominal pain, tarry stools, or other signs of intestinal bleeding, stop taking Urocit®-K and see your doctor right away. These could be signs of a serious condition such as a perforated or blocked bowel.

To report negative side effects, contact Mission Pharmacal Company at 1-800-298-1087 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  1. Chandhoke PS.. Evaluation of the recurrent stone former. Urol Clin North Am. 2007 Aug;34(3):315-22.
  2. Lotan Y. Economics and cost of care of kidney stone disease. Advances Chronic Kidney Dis. 2009;16:5-10.
  3. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
  4. Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985 Jul;134(1):11-9.
  5. Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985 Jul;134(1):20-3.
  6. Pak CY, Peterson R, Sakhaee K, Fuller C, Preminger G, Reisch J. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med. 1985 Sep;79(3):284-8.